Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 23519018)

1.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR.

Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21.

2.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

3.

Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.

Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA.

J Immunother. 2010 Sep;33(7):672-83. doi: 10.1097/CJI.0b013e3181e475cd.

PMID:
20664359
4.

Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses.

Speiser DE.

Cancer Discov. 2013 Apr;3(4):379-81. doi: 10.1158/2159-8290.CD-13-0064.

5.

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A.

Cancer Res. 2009 Dec 15;69(24):9385-94. doi: 10.1158/0008-5472.CAN-09-0494. Epub .

6.
7.

Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.

Laurent J, Speiser DE, Appay V, Touvrey C, Vicari M, Papaioannou A, Canellini G, Rimoldi D, Rufer N, Romero P, Leyvraz S, Voelter V.

J Immunother. 2010 Sep;33(7):723-34. doi: 10.1097/CJI.0b013e3181ea7e6e.

PMID:
20664354
8.

[A malignus melanoma immunterápiájának lehetoségei].

Ladányi A.

Magy Onkol. 2003;47(1):113-7. Epub 2003 Apr 18. Review. Hungarian.

9.

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R.

J Clin Oncol. 2006 Nov 1;24(31):5060-9.

10.

Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.

Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.

Gene Ther. 2005 Jan;12(2):140-6.

PMID:
15496961
11.

The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.

Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.

Sci Transl Med. 2012 Aug 29;4(149):149ra120. doi: 10.1126/scitranslmed.3004306.

12.

TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.

Govers C, Sebestyén Z, Roszik J, van Brakel M, Berrevoets C, Szöőr Á, Panoutsopoulou K, Broertjes M, Van T, Vereb G, Szöllősi J, Debets R.

J Immunol. 2014 Nov 15;193(10):5315-26. doi: 10.4049/jimmunol.1302074. Epub 2014 Oct 15.

PMID:
25320284
13.

T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.

Straetemans T, Coccoris M, Berrevoets C, Treffers-Westerlaken E, Scholten CE, Schipper D, Ten Hagen TL, Debets R.

Hum Gene Ther. 2012 Feb;23(2):187-201. doi: 10.1089/hum.2010.126. Epub 2011 Dec 2.

PMID:
21958294
14.

Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.

Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM.

J Immunother. 2002 May-Jun;25(3):252-63.

15.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.

J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.

16.

Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C.

PLoS One. 2009;4(3):e4749. doi: 10.1371/journal.pone.0004749. Epub 2009 Mar 9.

17.

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. Epub 2002 Nov 11.

18.

Is antigen specificity the key to efficient adoptive T-cell therapy?

Labarriere N, Khammari A, Lang F, Dreno B.

Immunotherapy. 2011 Apr;3(4):495-505. doi: 10.2217/imt.11.16. Review.

PMID:
21463191
19.

Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.

Burns WR, Zheng Z, Rosenberg SA, Morgan RA.

Blood. 2009 Oct 1;114(14):2888-99. doi: 10.1182/blood-2009-01-199216. Epub 2009 Jul 9.

20.

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk